TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02600286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EllaOne
Description: * 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EllaOne
Description: * 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EllaOne
Description: * 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months.
Study: NCT04311658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate 40 MG
Description: one tablet of Isosorbide Mononitrate (40 mg) vaginally 3 hours prior to LNG- IUD insertion
Study: NCT02600286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EllaOne placebo
Description: * 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EllaOne placebo
Description: * 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EllaOne placebo
Description: * 5 mg/per os of EllaOne every day through 12 months.~* 10 mg/per os of EllaOne every day through 12 months.~* EllaOne placebo/per os every day through 12 months.
Study: NCT04389320

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: assess its role in the coarse of covid 19 virus infection
Study: NCT02476799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectus sheath block
Description: Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bandage
Description: After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bandage
Description: After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: IV-PCA containing Fentanyl and Ketorolac
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
Study: NCT03219658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting education sessions
Description: If assigned to the parenting education session group, families will start with the 10-week group parenting education sessions and 2-4 home visits immediately after being enrolled. During this time, they will also come in for four one-on-one check-ins with the STOMP team. Each check-in will be approximately 1 hour. At least one parent/caregiver will attend weekly parenting sessions which will take place at SickKids. The Toronto Public Health Nurse will arrange 2-4 home visits with the family during the 6 month period of the study. The home visits will focus on helping to apply the messages and skills from the group sessions in their homes, and making connections in the neighbourhood to recreational or nutrition programs or other supports for the family.
Study: NCT03708887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose omega-3 fatty acid supplementation
Description: Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose omega-3 fatty acid supplementation
Description: Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control drug
Description: Matching placebo capsules,3 g/d by mouth for 1 year
Study: NCT00924040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL22 (CAT-3888)
Description: 30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
Study: NCT01062178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
Study: NCT05986201

Intervention type: DEVICE
Intervention: TachoSil®
Description: TachoSil®, a carrier-bound fibrin sealant (CBFS), is a haemostatic tissue sealant composed of a collagen sponge, made from horse tendons, coated on one side with dried human fibrinogen and human thrombin.
Study: NCT04311658

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet of placebo vaginally 3 hours prior to LNG-IUD insertion
Study: NCT01289496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alpha-2a, Ribavirin
Description: * 4 weeks RBV priming;~* 24 or 48 weeks of Pegasys+Ribavirin (RBV) Treatment (depending on genotype);~* 24 weeks Follow-Up~Patients will receive PEGASYS® 180 µg in 0.5 mL (prefilled syringes) administered sc once weekly. Specific guidelines for adjusting the dose of PEGASYS® are provided in the product monograph.All PEGASYS® administrations will be via the sc route using sterile technique.~Ribavirin 200 mg tablets
Study: NCT04343651

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leronlimab (700mg)
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Study: NCT01506882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: LEV 250 mg, LEV 500 mg~* Frequency: Twice daily~* Route of Administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: LEV 250 mg, LEV 500 mg~* Frequency: Twice daily~* Route of Administration: Oral use
Study: NCT02129673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS101 Insert Dose A
Description: Sustained release of latanoprost into the eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS101 Insert Dose B
Description: Sustained release of latanoprost into the eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS101 Insert Dose C
Description: Sustained release of latanoprost into the eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% eye drops
Description: Latanoprost 0.005% eye drops administered once daily on the eye
Study: NCT01468311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auto stem cell transplant
Description: Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
Study: NCT02476799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV-PCA containing Fentanyl and Ketorolac
Description: All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
Study: NCT02646397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosinopril
Description: Fosinopril is an angiotensin-converting enzyme inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosinopril
Description: Fosinopril is an angiotensin-converting enzyme inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benidipine
Description: Benidipine is a dihydropyridine-derived calcium channel blocker.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide is a diuretic medication.
Study: NCT04048369

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid diagnosis of influenza in the emergency medical service
Description: Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid diagnosis of influenza in the emergency medical service
Description: Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
Study: NCT02886208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measurement
Description: The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
Study: NCT00477516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exposure to a high-calcium dialysate bath
Description: Subjects are exposed to a high calcium (3.5 mEq/L) dialysate bath for 150 minutes (part 1). At defined timepoints (0, 45, 90, and 150 min) blood is sampled for calcium, PTH, phosphorous, and FGF-23. At another (later) dialysis session (part 2), the process is repeated except that the subjects are exposed to a normal calcium bath (2.5 mEq/L). For each subject, results from part 1 are compared to the results from part 2.
Study: NCT03044171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Laser therapy: it was used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and central-medial region of the incisors, canines and premolars.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1% Sodium Fluoride
Description: Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
Study: NCT01468311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM
Description: BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 111In-daclizumab
Description: 111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90Y-daclizumab
Description: 90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
Study: NCT03044171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1% Sodium Fluoride
Description: Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-office dental bleaching
Description: Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
Study: NCT03629548

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early amniotomy
Description: 10 mg PGE2 vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foley catheter balloon placement
Description: an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg PGE2 vaginal ovul will be inserted to the posterior fornix
Study: NCT03044171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: In-office dental bleaching
Description: Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
Study: NCT02865746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bethametasone
Description: The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
Study: NCT00864097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 10 mg every 8 weeks (through Week 16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac
Description: Oral diclofenac SR 75 mg BID for 32 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 5 mg every 8 weeks (through Week 16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac
Description: Oral diclofenac SR 75 mg BID for 32 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: IV tanezumab 2.5 mg every 8 weeks (through Week 16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac
Description: Oral diclofenac SR 75 mg BID for 32 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diclofenac
Description: Oral diclofenac SR 75 mg BID for 32 weeks
Study: NCT01849744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-4718
Study: NCT04134546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBD exoloration
Description: Early versus late intervention after biliary tract injury post cholecystectomy
Study: NCT00864097

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: IV placebo to match tanezumab every 8 weeks (through Week 16)
Study: NCT04206410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Multispecies probiotic mixture administered to patients according to the randomization list

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin as placebo
Study: NCT00545545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Safety and efficacy of escalating doses
Description: Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle) and irinotecan on Day 1 of each week for 4 weeks with a 2-week rest. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Safety and efficacy of escalating doses
Description: Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle) and irinotecan on Day 1 of each week for 4 weeks with a 2-week rest. Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Safety and efficacy of escalating doses
Description: Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle) and irinotecan on Day 1 of each week for 4 weeks with a 2-week rest. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT04150367

Intervention type: DRUG
Intervention: Isoniazid
Description: Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.

Intervention type: DRUG
Intervention: Rifampicin
Description: Participants will get the dosage according to the instruction for use.

Intervention type: DRUG
Intervention: Ethambutol
Description: Participants will get the dosage according to the instruction for use.
Study: NCT00545545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Safety and efficacy of escalating doses.
Description: Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT04201080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: TRV250-20mg/ml
Description: TRV250 SC Injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: TRV250 Dose 1
Description: Dose 1of3 TRV250
Study: NCT00545545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Safety and efficacy of escalating doses.
Description: Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Safety and efficacy of escalating doses.
Description: Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT01558141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration without flushing follicles with culture media
Description: Aspiration without flushing follicles with culture media.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follicular Flushing
Description: Flushing follicles with embryo culture media prior to aspiration.
Study: NCT02609139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Up to 400mg modified release tablets administered under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 100mg modified release tablet administered under fasted conditions
Study: NCT04201080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: TRV250 Dose 2
Description: Dose 2of3 TRV250 SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: TRV250 Dose 3
Description: Dose 3of3 TRV250 SC injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC injections
Study: NCT02676830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312 100 mg
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-312 100 ug C14 IV
Description: microtracer dose containing ≤37 kBq (1000 nCi) \[14C\] given as a 5-ml IV push over 2 minutes
Study: NCT03551587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibringe
Description: The Vibringe is the first endodontic sonic irrigation system that enables delivery and activation of the irrigation solution in the root canal, in only one step.
Study: NCT04150367

Intervention type: DRUG
Intervention: Rifampicin
Description: Participants will get the dosage according to the instruction for use.

Intervention type: DRUG
Intervention: Isoniazid
Description: . Participants will get the dosage according to the instruction for use.
Study: NCT02609139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 20mg modified release tablet administered under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Up to 400mg modified release tablets administered with high fat meal food intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 100mg modified released tablet administered with high fat meal food intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: 20 mg modified release tablet administered with high fat meal food intake
Study: NCT03705065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)
Study: NCT04394676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure applied during RARP
Description: Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 12 mmHg (experimental) or 15mm Hg (standard technique).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure applied during RARP
Description: Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 12 mmHg (experimental) or 15mm Hg (standard technique).
Study: NCT03192930

Intervention type: OTHER
Intervention: Hyperbaric exposure
Description: Hyperbaric exposure 4 ATA for 36 hours followed by 70 hours decompression
Study: NCT03806777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Highly selective alpha-2 adrenergic agonist with sedative properties.
Study: NCT02183688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose ASA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ASA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose ASA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03085056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: trametinib orally 2mg daily during each 4 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 80mg/m\^2 weekly for 3 out of 4 weeks
Study: NCT01448057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
Description: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (500 mg) tablets
Description: Paracetamol (500 mg) tablets
Study: NCT03481647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral care programme
Description: Professional oral care (dental hygienist), intensified oral care measures by the patient
Study: NCT04172454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104, 6mg/kg, Q2W